{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:13:10Z","timestamp":1790190790764,"version":"4.1.0"},"reference-count":106,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Shanghai Municipality Science and Technology Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.autrev.2021.102800","type":"journal-article","created":{"date-parts":[[2021,3,14]],"date-time":"2021-03-14T00:51:20Z","timestamp":1615683080000},"page":"102800","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["The role of innate immunity in myasthenia gravis"],"prefix":"10.1016","volume":"20","author":[{"given":"Rui","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongbo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2021.102800_bb0005","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/cei.12217","article-title":"Myasthenia gravis: an update for the clinician","volume":"175","author":"Sieb","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2021.102800_bb0010","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1375\/twin.14.2.129","article-title":"Utilizing twins concordance rates to infer the predisposition to myasthenia gravis","volume":"14","author":"Ramanujam","year":"2011","journal-title":"Twin Res Hum Genet"},{"key":"10.1016\/j.autrev.2021.102800_bb0015","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.4049\/jimmunol.167.4.1935","article-title":"Somatic hypermutation and selection of B cells in thymic germinal centers responding to acetylcholine receptor in myasthenia gravis","volume":"167","author":"Sims","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2021.102800_bb0020","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.autrev.2018.10.005","article-title":"Innate immune-responses and their role in driving autoimmunity","volume":"18","author":"Toubi","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102800_bb0025","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1212\/WNL.0000000000003697","article-title":"Zika virus infection and myasthenia gravis: report of 2 cases","volume":"88","author":"Molko","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2021.102800_bb0030","first-page":"1","article-title":"New onset of ocular myasthenia gravis in a patient with COVID-19: a novel case report and literature review","author":"Sriwastava","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2021.102800_bb0035","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1177\/08830738050200051501","article-title":"Postinfectious myasthenia gravis: report of two children","volume":"20","author":"Felice","year":"2005","journal-title":"J Child Neurol"},{"key":"10.1016\/j.autrev.2021.102800_bb0040","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4103\/sjmms.sjmms_118_18","article-title":"Seronegative myasthenia gravis in association with human T-Lymphotropic virus type 1 and hepatitis C","volume":"7","author":"Amin","year":"2019","journal-title":"Saudi J Med & Med Sci"},{"key":"10.1016\/j.autrev.2021.102800_bb0045","doi-asserted-by":"crossref","first-page":"102382","DOI":"10.1016\/j.jaut.2019.102382","article-title":"Innate immunity as the trigger of systemic autoimmune diseases","volume":"110","author":"Saferding","year":"2020","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2021.102800_bb0050","doi-asserted-by":"crossref","first-page":"102430","DOI":"10.1016\/j.autrev.2019.102430","article-title":"Multiple sclerosis, the microbiome, TLR2, and the hygiene hypothesis","volume":"19","author":"Wasko","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102800_bb0055","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.autrev.2019.06.009","article-title":"P2X7 receptor: a potential therapeutic target for autoimmune diseases","volume":"18","author":"Cao","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102800_bb0060","doi-asserted-by":"crossref","first-page":"102584","DOI":"10.1016\/j.autrev.2020.102584","article-title":"Pentraxin 3: a promising therapeutic target for autoimmune diseases","volume":"19","author":"Wu","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102800_bb0065","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41575-019-0261-4","article-title":"Epithelial toll-like receptors and their role in gut homeostasis and disease","volume":"17","author":"Burgue\u00f1o","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2021.102800_bb0070","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.cell.2010.01.022","article-title":"Pattern recognition receptors and inflammation","volume":"140","author":"Takeuchi","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2021.102800_bb0075","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/ana.21902","article-title":"Epstein-Barr virus persistence and reactivation in myasthenia gravis thymus","volume":"67","author":"Cavalcante","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2021.102800_bb0080","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1212\/WNL.0b013e3181d7d884","article-title":"Detection of poliovirus-infected macrophages in thymus of patients with myasthenia gravis","volume":"74","author":"Cavalcante","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2021.102800_bb0085","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in Myasthenia Gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"New England J Med"},{"key":"10.1016\/j.autrev.2021.102800_bb0090","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.autrev.2018.07.011","article-title":"Characterization of the thymus in Lrp4 myasthenia gravis: four cases","volume":"18","author":"Koneczny","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102800_bb0095","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.neurol.2013.02.005","article-title":"The thymus in autoimmune Myasthenia Gravis: paradigm for a tertiary lymphoid organ","volume":"169","author":"Weiss","year":"2013","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.autrev.2021.102800_bb0100","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/nyas.13519","article-title":"Thymus involvement in early-onset myasthenia gravis","volume":"1412","author":"Cron","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2021.102800_bb0105","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2353\/ajpath.2007.070240","article-title":"Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status","volume":"171","author":"Leite","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.autrev.2021.102800_bb0110","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1196\/annals.1405.019","article-title":"Regulatory and pathogenic mechanisms in human autoimmune myasthenia gravis","volume":"1132","author":"Le Panse","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2021.102800_bb0115","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/ng.3680","article-title":"Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants","volume":"48","author":"Jin","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.autrev.2021.102800_bb0120","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1001\/jamaneurol.2014.4103","article-title":"A genome-wide association study of myasthenia gravis","volume":"72","author":"Renton","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2021.102800_bb0125","doi-asserted-by":"crossref","first-page":"102349","DOI":"10.1016\/j.autrev.2019.102349","article-title":"HLA in myasthenia gravis: from superficial correlation to underlying mechanism","volume":"18","author":"Zhong","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102800_bb0130","doi-asserted-by":"crossref","first-page":"102496","DOI":"10.1016\/j.autrev.2020.102496","article-title":"Polymorphism of toll-like receptor genes and autoimmune endocrine diseases","volume":"19","author":"Dvornikova","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102800_bb0135","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/ana.23691","article-title":"Risk for myasthenia gravis maps to a (151) Pro\u2192Ala change in TNIP1 and to human leukocyte antigen-B*08","volume":"72","author":"Gregersen","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2021.102800_bb0140","doi-asserted-by":"crossref","first-page":"3491269","DOI":"10.1155\/2018\/3491269","article-title":"TNIP1 in autoimmune diseases: regulation of toll-like receptor signaling","volume":"2018","author":"Shamilov","year":"2018","journal-title":"J Immunol Res"},{"key":"10.1016\/j.autrev.2021.102800_bb0145","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1084\/jem.20102177","article-title":"Polyubiquitin binding to ABIN1 is required to prevent autoimmunity","volume":"208","author":"Nanda","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2021.102800_bb0150","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cytogfr.2012.04.002","article-title":"Emerging roles for TNIP1 in regulating post-receptor signaling","volume":"23","author":"Ramirez","year":"2012","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.autrev.2021.102800_bb0155","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.gene.2018.05.062","article-title":"Association of TNFAIP3 and TNIP1 polymorphisms with systemic lupus erythematosus risk: a meta-analysis","volume":"668","author":"Liu","year":"2018","journal-title":"Gene"},{"key":"10.1016\/j.autrev.2021.102800_bb0160","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s00018-016-2167-4","article-title":"Contribution of MicroRNAs to autoimmune diseases","volume":"73","author":"Garo","year":"2016","journal-title":"Cell Mol Life Sci\u202f: CMLS"},{"key":"10.1016\/j.autrev.2021.102800_bb0165","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1038\/leu.2012.108","article-title":"Differential regulation of miR-21 and miR-146a by Epstein-Barr virus-encoded EBNA2","volume":"26","author":"Rosato","year":"2012","journal-title":"Leukemia"},{"issue":"Suppl. 2","key":"10.1016\/j.autrev.2021.102800_bb0170","doi-asserted-by":"crossref","first-page":"ii90","DOI":"10.1136\/annrheumdis-2012-202203","article-title":"MicroRNA-146a in autoimmunity and innate immune responses","volume":"72","author":"Chan","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102800_bb0175","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.coi.2012.07.011","article-title":"MicroRNAs and autoimmunity","volume":"24","author":"Ceribelli","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.autrev.2021.102800_bb0180","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3389\/fimmu.2020.00142","article-title":"miR-146a in myasthenia gravis thymus bridges innate immunity with autoimmunity and is linked to therapeutic effects of corticosteroids","volume":"11","author":"Bortone","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2021.102800_bb0185","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nri1391","article-title":"Toll-like receptor signalling","volume":"4","author":"Akira","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2021.102800_bb0190","doi-asserted-by":"crossref","first-page":"95432","DOI":"10.18632\/oncotarget.20731","article-title":"Epstein-Barr virus in tumor-infiltrating B cells of myasthenia gravis thymoma: an innocent bystander or an autoimmunity mediator?","volume":"8","author":"Cavalcante","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.autrev.2021.102800_bb0195","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/ana.23791","article-title":"Implication of double-stranded RNA signaling in the etiology of autoimmune myasthenia gravis","volume":"73","author":"Cufi","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2021.102800_bb0200","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1600-065X.2012.01124.x","article-title":"Germinal center selection and the development of memory B and plasma cells","volume":"247","author":"Shlomchik","year":"2012","journal-title":"Immunol Rev"},{"key":"10.1016\/j.autrev.2021.102800_bb0205","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/ana.21628","article-title":"CCL21 overexpressed on lymphatic vessels drives thymic hyperplasia in myasthenia","volume":"66","author":"Berrih-Aknin","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2021.102800_bb0210","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jaut.2013.12.016","article-title":"Central role of interferon-beta in thymic events leading to myasthenia gravis","volume":"52","author":"Cufi","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2021.102800_bb0215","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.immuni.2011.10.015","article-title":"Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation","volume":"35","author":"Peters","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2021.102800_bb0220","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaut.2018.11.005","article-title":"Il-23\/Th17 cell pathway: a promising target to alleviate thymic inflammation maintenance in myasthenia gravis","volume":"98","author":"Villegas","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2021.102800_bb0225","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0002-9440(10)62960-4","article-title":"Increased toll-like receptor 4 expression in Thymus of Myasthenic patients with Thymitis and Thymic involution","volume":"167","author":"Bernasconi","year":"2005","journal-title":"Am J Pathol"},{"key":"10.1016\/j.autrev.2021.102800_bb0230","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.imbio.2015.12.007","article-title":"Increased expression of Toll-like receptors 7 and 9 in myasthenia gravis thymus characterized by active Epstein-Barr virus infection","volume":"221","author":"Cavalcante","year":"2016","journal-title":"Immunobiology"},{"key":"10.1016\/j.autrev.2021.102800_bb0235","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10753-012-9526-6","article-title":"Possible involvement of toll-like receptors in the pathogenesis of myasthenia gravis","volume":"36","author":"Wang","year":"2013","journal-title":"Inflammation"},{"key":"10.1016\/j.autrev.2021.102800_bb0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2018.09.015","article-title":"West Nile virus induces a post-infectious pro-inflammatory state that explains transformation of stable ocular myasthenia gravis to myasthenic crises","volume":"395","author":"Hawkes","year":"2018","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.autrev.2021.102800_bb0245","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/ni1457","article-title":"Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE","volume":"8","author":"Tian","year":"2007","journal-title":"Nat Immunol"},{"key":"10.1016\/j.autrev.2021.102800_bb0250","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.molimm.2018.01.005","article-title":"Toll-like receptor 9 antagonist suppresses humoral immunity in experimental autoimmune myasthenia gravis","volume":"94","author":"Zhang","year":"2018","journal-title":"Mol Immunol"},{"key":"10.1016\/j.autrev.2021.102800_bb0255","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21134645","article-title":"Synergistic activation of toll-like and NOD receptors by complementary antigens as facilitators of autoimmune disease: review, model and novel predictions","volume":"21","author":"Root-Bernstein","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2021.102800_bb0260","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s12016-016-8549-4","article-title":"Review on toll-like receptor activation in myasthenia gravis: application to the development of new experimental models","volume":"52","author":"Robinet","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2021.102800_bb0265","doi-asserted-by":"crossref","first-page":"37427","DOI":"10.1074\/jbc.M605311200","article-title":"The functional effects of physical interactions among toll-like receptors 7, 8, and 9","volume":"281","author":"Wang","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.autrev.2021.102800_bb0270","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/nyas.13534","article-title":"Toll-like receptors 7 and 9 in myasthenia gravis thymus: amplifiers of autoimmunity?","volume":"1413","author":"Cavalcante","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2021.102800_bb0275","doi-asserted-by":"crossref","first-page":"9748","DOI":"10.1128\/JVI.01122-07","article-title":"Manipulation of the toll-like receptor 7 signaling pathway by Epstein-Barr virus","volume":"81","author":"Martin","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.autrev.2021.102800_bb0280","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1084\/jem.147.4.973","article-title":"Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis","volume":"147","author":"Lennon","year":"1978","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2021.102800_bb0285","doi-asserted-by":"crossref","first-page":"5743","DOI":"10.4049\/jimmunol.172.9.5743","article-title":"Circulating immune complexes augment severity of antibody-mediated myasthenia gravis in hypogammaglobulinemic RIIIS\/J mice","volume":"172","author":"T\u00fcz\u00fcn","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2021.102800_bb0290","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jneuroim.2006.10.014","article-title":"Pros and cons of treating murine myasthenia gravis with anti-C1q antibody","volume":"182","author":"T\u00fcz\u00fcn","year":"2007","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2021.102800_bb0295","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jaut.2013.01.003","article-title":"Complement C2 siRNA mediated therapy of myasthenia gravis in mice","volume":"42","author":"Huda","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2021.102800_bb0300","first-page":"213092","article-title":"Inflammation and epstein-barr virus infection are common features of myasthenia gravis thymus: possible roles in pathogenesis","volume":"2011","author":"Cavalcante","year":"2011","journal-title":"Autoimmune Dis"},{"key":"10.1016\/j.autrev.2021.102800_bb0305","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.4049\/jimmunol.171.7.3847","article-title":"Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis","volume":"171","author":"Tuzun","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2021.102800_bb0310","doi-asserted-by":"crossref","first-page":"8562","DOI":"10.4049\/jimmunol.179.12.8562","article-title":"Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis","volume":"179","author":"Zhou","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2021.102800_bb0315","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/ana.21536","article-title":"Novel complement inhibitor limits severity of experimentally myasthenia gravis","volume":"65","author":"Soltys","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2021.102800_bb0320","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1365-2249.2006.03198.x","article-title":"Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats","volume":"146","author":"Chamberlain-Banoub","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2021.102800_bb0325","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1365-2249.2006.03205.x","article-title":"The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice","volume":"146","author":"Morgan","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2021.102800_bb0330","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1172\/JCI0216086","article-title":"Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection","volume":"110","author":"Lin","year":"2002","journal-title":"J Clin Investig"},{"key":"10.1016\/j.autrev.2021.102800_bb0335","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/mus.24057","article-title":"Targeting therapy to the neuromuscular junction: proof of concept","volume":"49","author":"Kusner","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2021.102800_bb0340","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.autrev.2017.11.018","article-title":"NK cells in autoimmune diseases: linking innate and adaptive immune responses","volume":"17","author":"Gianchecchi","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102800_bb0345","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1084\/jem.192.11.1553","article-title":"CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function","volume":"192","author":"Schaerli","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2021.102800_bb0350","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12974-019-1687-x","article-title":"CXCR5-negative natural killer cells ameliorate experimental autoimmune myasthenia gravis by suppressing follicular helper T cells","volume":"16","author":"Yang","year":"2019","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.autrev.2021.102800_bb0355","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/79792","article-title":"Natural killer cells determine the outcome of B cell-mediated autoimmunity","volume":"1","author":"Shi","year":"2000","journal-title":"Nat Immunol"},{"key":"10.1016\/j.autrev.2021.102800_bb0360","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/j.1468-1331.2011.03424.x","article-title":"Inhibition of peripheral blood natural killer cell cytotoxicity in patients with myasthenia gravis treated with plasmapheresis","volume":"18","author":"Chien","year":"2011","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.autrev.2021.102800_bb0365","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","article-title":"Biology and regulation of IL-2: from molecular mechanisms to human therapy","volume":"18","author":"Spolski","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2021.102800_bb0370","doi-asserted-by":"crossref","first-page":"7898","DOI":"10.4049\/jimmunol.175.12.7898","article-title":"Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia","volume":"175","author":"Liu","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2021.102800_bb0375","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12974-015-0334-4","article-title":"Caspase-1 inhibitor ameliorates experimental autoimmune myasthenia gravis by innate dendric cell IL-1-IL-17 pathway","volume":"12","author":"Wang","year":"2015","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.autrev.2021.102800_bb0380","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1074\/jbc.M114.591420","article-title":"MicroRNA-146a and microRNA-146b regulate human dendritic cell apoptosis and cytokine production by targeting TRAF6 and IRAK1 proteins","volume":"290","author":"Park","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.autrev.2021.102800_bb0385","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1007\/s10753-017-0589-2","article-title":"Immature Exosomes derived from MicroRNA-146a overexpressing dendritic cells act as antigen-specific therapy for myasthenia gravis","volume":"40","author":"Yin","year":"2017","journal-title":"Inflammation"},{"key":"10.1016\/j.autrev.2021.102800_bb0390","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1182\/blood-2004-02-0412","article-title":"RelB regulates human dendritic cell subset development by promoting monocyte intermediates","volume":"104","author":"Platzer","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2021.102800_bb0395","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00011-009-0087-6","article-title":"Suppression of ongoing experimental autoimmune myasthenia gravis by transfer of RelB-silenced bone marrow dentritic cells is associated with a change from a T helper Th17\/Th1 to a Th2 and FoxP3+ regulatory T-cell profile","volume":"59","author":"Yang","year":"2010","journal-title":"Inflamm Res"},{"key":"10.1016\/j.autrev.2021.102800_bb0400","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis - autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.autrev.2021.102800_bb0405","doi-asserted-by":"crossref","first-page":"102712","DOI":"10.1016\/j.autrev.2020.102712","article-title":"Update in immunosuppressive therapy of myasthenia gravis","volume":"20","author":"Lascano","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102800_bb0410","doi-asserted-by":"crossref","DOI":"10.1177\/1756285617749134","article-title":"When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies","volume":"11","author":"Mantegazza","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.autrev.2021.102800_bb0415","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/s12883-019-1573-2","article-title":"Understanding side effects of therapy for myasthenia gravis and their impact on daily life","volume":"19","author":"Bacci","year":"2019","journal-title":"BMC Neurol"},{"key":"10.1016\/j.autrev.2021.102800_bb0420","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1212\/WNL.49.6.1747-a","article-title":"Onset of myasthenia gravis in a patient with multiple sclerosis during interferon-1b treatment","volume":"49","author":"Blake","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2021.102800_bb0425","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1159\/000334128","article-title":"Myasthenia gravis during the course of Neuromyelitis Optica","volume":"3","author":"Etemadifar","year":"2011","journal-title":"Case Rep Neurol"},{"key":"10.1016\/j.autrev.2021.102800_bb0430","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1136\/jnnp.2003.028233","article-title":"Development of myasthenia gravis in two patients with multiple sclerosis following interferon beta treatment","volume":"75","author":"Dionisiotis","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2021.102800_bb0435","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1136\/ard.2004.033753","article-title":"Type I interferon correlates with serological and clinical manifestations of SLE","volume":"64","author":"Dall\u2019era","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102800_bb0440","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of Anifrolumab in active systemic lupus Erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2021.102800_bb0445","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus Erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102800_bb0450","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1080\/13543776.2016.1185415","article-title":"Recent progress in the development of Toll-like receptor (TLR) antagonists","volume":"26","author":"Patra","year":"2016","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.autrev.2021.102800_bb0455","first-page":"A95","article-title":"A phase I, first-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of M5049, a dual antagonist of TLR7\/8, in healthy subjects","volume":"7","author":"Port","year":"2020","journal-title":"Lupus Sci Med"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2021.102800_bb0460","first-page":"A28","article-title":"M5049, a novel potent and selective inhibitor of toll-like receptors 7 and 8 (TLR 7\/8)","volume":"7","author":"Sherer","year":"2020","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.autrev.2021.102800_bb0465","first-page":"S26","article-title":"IMO-3100, an antagonist of toll-like receptor (TLR) 7 and TLR9, demonstrates clinical activity in psoriasis patients with 4 weeks of treatment in a phase 2a trial","volume":"133","author":"Kimball","year":"2013","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.autrev.2021.102800_bb0470","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3389\/fimmu.2020.00917","article-title":"Complement inhibitor therapy for myasthenia gravis","volume":"11","author":"Albazli","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2021.102800_bb0475","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"issue":"2020","key":"10.1016\/j.autrev.2021.102800_bb0480","article-title":"Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab","volume":"267","author":"Vissing","year":"1991","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2021.102800_bb0485","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mus.23839","article-title":"A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis","volume":"48","author":"Howard","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2021.102800_bb0490","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2021.102800_bb0495","doi-asserted-by":"crossref","first-page":"116419","DOI":"10.1016\/j.jns.2019.08.004","article-title":"Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: a subgroup analysis of the REGAIN open-label extension study","volume":"407","author":"Murai","year":"2019","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.autrev.2021.102800_bb0500","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420904207","article-title":"Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis","volume":"13","author":"Oyama","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"issue":"Suppl. 2","key":"10.1016\/j.autrev.2021.102800_bb0505","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.cmi.2018.02.002","volume":"24","author":"Winthrop","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.autrev.2021.102800_bb0510","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","article-title":"Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, Multicenter Clinical Trial","volume":"77","author":"Howard","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2021.102800_bb0515","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40265-019-01068-2","article-title":"Ravulizumab: First Global Approval","volume":"79","author":"McKeage","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.autrev.2021.102800_bb0520","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1716995","article-title":"Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema","volume":"379","author":"Ayg\u00f6ren-P\u00fcrs\u00fcn","year":"2018","journal-title":"New England J Med"},{"key":"10.1016\/j.autrev.2021.102800_bb0525","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1613627","article-title":"Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor","volume":"376","author":"Longhurst","year":"2017","journal-title":"New England J Med"},{"key":"10.1016\/j.autrev.2021.102800_bb0530","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1097\/TP.0000000000002717","article-title":"Update on C1 esterase inhibitor in human solid organ transplantation","volume":"103","author":"Berger","year":"2019","journal-title":"Transplantation"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221000641?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221000641?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:22:08Z","timestamp":1761600128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997221000641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":106,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S1568997221000641"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102800","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of innate immunity in myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102800","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102800"}}